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Major Postoperative Complications Are a Risk Factor
for Impaired Survival after CRS/HIPEC
Marcel Andre´ Schneider, M Med, Dilmurodjon Eshmuminov, MD, and Kuno Lehmann, MD, PhD
Department of Visceral and Transplantation Surgery, University Hospital of Zurich, Zurich, Switzerland
ABSTRACT
Background. Cytoreductive surgery (CRS) and hyper-
thermic intraperitoneal chemotherapy (HIPEC) is a
combined treatment option for well-selected patients with
peritoneal carcinomatosis (PC). The study aimed to iden-
tify factors influencing cancer-specific survival (CSS) and
disease-free survival (DFS).
Methods. Data of 113 patients with colorectal or appen-
dicular carcinomatosis from a single center operated
between 2009 and 2014 were retrospectively collected and
analyzed. Patients with high-grade tumors received stan-
dard perioperative chemotherapy, and patients with low-
grade appendix tumors were directly operated. HIPEC was
performed after radical CRS.
Results. Patients had carcinomatosis from appendix neo-
plasms in 63% (71/113), including low-grade and high-
grade tumors, and colorectal cancer in 37% (42/113).
Complete cytoreduction and HIPEC were possible in 67%
of patients. Major morbidity occurred in 10.6% of patients,
and mean follow-up was 28 months. For colorectal PC,
median CSS and DFS were 40 and 12 months, respec-
tively. Median DFS was 19 months for high-grade
appendix tumors, while median CSS has not been reached.
All patients with diffuse peritoneal adenomucinosis were
still alive at time of analysis; rate of DFS was 96% for
these patients after 3 years. Major postoperative compli-
cations (Clavien-Dindo IIIB or higher) and positive nodal
state were associated with impaired CSS and DFS, while a
peritoneal cancer index score of[10 was independently
associated with impaired CSS.
Conclusions. CRS/HIPEC offers a survival benefit in
well-selected patients with PC. Major postoperative com-
plications affect long-term oncologic outcome of these
patients.
The combination of radical cytoreductive surgery (CRS)
and hyperthermic intraperitoneal chemotherapy (HIPEC)
can improve cancer-specific survival (CSS) in well-se-
lected patients with peritoneal carcinomatosis (PC) of
colorectal (CRC) or appendix tumors.1 The outcome
depends on multiple factors, such as the subtype of the
primary tumor, the extent of carcinomatosis as defined by
the peritoneal cancer index (PCI), and the radicality of
surgery (completeness of cytoreduction [CC] score).2
Modern systemic therapy has made tremendous advances,
and recent regimens—for example, the combination of
FOLFOXIRI and bevacizumab—provide a median pro-
gression-free and overall survival (OS) of 12 and
31 months, respectively.3 However, a previous subgroup
analysis of 2 randomized trials suggests an impaired sur-
vival for patients with PC compared to other hematogenous
metastatic sites.4
Despite the availability of a randomized trial, the benefit
of CRS/HIPEC over modern systemic chemotherapy alone
has not yet been proven.5,6 This is mostly due to method-
ologic shortcomings, such as the availability of novel
agents for the control group, and different operative
strategies or selection criteria. For CRC and appendicular
tumors, however, there is evidence from multicenter data-
bases and case series showing better OS for colorectal
patients and long-term disease-free survival (DFS) for low-
malignant appendix tumors.2,7 Furthermore, it has been
shown that this maximally invasive procedure can be per-
formed with acceptable mortality and morbidity rates.8 As
a consequence, CRS/HIPEC became a treatment option for
many patients with peritoneal surface malignancies.
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The critical question today is the selection of patients for
CRS/HIPEC to avoid unnecessary procedures in patients
who will not benefit from surgical treatment. Preopera-
tively known clinical disease criteria may help select
patients. This is probably the true benefit of analyses of
patient registry outcomes while still awaiting results from
randomized trials.
We retrospectively analyzed CSS and DFS of a patient
cohort with PC from appendiceal or CRC origin and per-
formed univariate and multivariate analysis to identify
factors predicting outcome in regard to CSS and DFS.
Furthermore, we analyzed the recurrence patterns to gain a
better understanding about disease relapse after CRS/
HIPEC.
METHODS
A complete cohort of patients with PC of CRC of
appendiceal origin scheduled for CRS/HIPEC in our
department between January 2009 and December 2014 was
analyzed. The primary outcome was CSS from the date of
the operation. Secondary outcomes were DFS, determina-
tion of patterns of recurrence, and identification of factors
predicting CSS and DFS. The study was approved by the
responsible ethics committee (KEK-ZH-Nr. 2016-00118)
of the cantonal authorities in Zurich, Switzerland.
Patients were selected for CRS/HIPEC after clinical
assessment and exclusion of extra-abdominal tumor man-
ifestations by positron emission tomography/computed
tomography. All patients were presented in a multidisci-
plinary tumor board before treatment. Patients with CRC or
high-grade (HG) appendiceal tumors received standard-of-
care perioperative chemotherapy based on leucovorin,
5-fluorouracil, irinotecan and/or oxaliplatin in combination
with monoclonal antibodies targeting angiogenesis where
appropriate. Patients with low-grade (LG) appendix tumors
were directly operated. The group of LG appendiceal
neoplasms corresponds to the entity of diffuse peritoneal
adenomucinosis (DPAM) according to the classification of
Ronnett et al.9 The HG appendix tumor group includes
mucinous tumors with high cellularity (peritoneal muci-
nous carcinoma, PMCA) and adenocarcinomas of intestinal
or signet-ring type. Anesthesia was conducted with
propofol and volatile anesthetics combined with thoracic
epidural anaesthesia as described previously.10 HIPEC was
performed with an open abdomen/colosseum technique as
specified elsewhere, using 1.5% glucose peritoneal dialysis
solution for perfusion.11,12 Mitomycin C (30 mg/m2) and
doxorubicin (15 mg/m2) were used in combination in all
cases. A complete procedure was defined as radical CRS
(CC score of 0 for HG appendix tumors/CRC and CC score
of 0 or 1 in case of LG appendiceal neoplasms/DPAM)
followed by HIPEC in full concentration at 42 C over
90 min. Follow-up included clinical examinations, tumor
markers, and computed tomographic scans every 6 months.
Adjuvant chemotherapy was provided according to rec-
ommendations of an interdisciplinary tumor board.
Statistics
Continuous data are provided as median ± interquartile
range (IQR). The Mann–Whitney U test or Pearson’s Chi
square test was used to compare medians and their
respective odds in the baseline groups. Kaplan–Meier
curves and survival tables were calculated to determine
CSS and DFS in subgroups from the date of the operation
until date of cancer-related death, disease progression, or
date of last follow-up in months. The Mantel-Cox log rank
test was used to test for differences between survival
curves. Univariate and multivariate analyses were per-
formed by Cox regression. Results of the univariate
analysis were bias corrected by bootstrapping 1000 sam-
ples. Multivariate analysis was performed with a backward
conditional likelihood ratio model with initial inclusion of
all variables and consequent stepwise exclusion. Missing
values were replaced with the mean of the respective
variable for multivariate analyses. All statistical analyses
were performed by IBM SPSS 23 for Windows. Statistical
significance was defined as p\ 0.05.
RESULTS
Patient Characteristics
Overall, 113 patients with PC of either appendiceal
origin (n = 71, 31 LG and 40 HG tumors) or CRC
(n = 42) were operated between January 2009 and
December 2014. Patients had a median age of 52 years
(IQR 43–59) and with an equal gender incidence (56 male
and 57 female patients). Mean follow-up at time of analysis
was 28 months. A complete procedure was possible in 76
patients (67.3%). Reasons for incomplete interventions
were preoperative underestimation of PC by imaging
modalities and inability to perform a complete resec-
tion. More precisely, in 12 patients the abdomen was
closed after laparotomy or laparoscopy and initial inspec-
tion, 10 patients received surgical cytoreduction without
HIPEC, and 15 patients had CRS/HIPEC but without
achieving a CC score of 0. Overall morbidity rate was
41.7%. Major complications, defined according to Clavien-
Dindo IIIB or higher (need for reoperation or intensive care
unit referral), occurred in 12 patients (10.6%).13 No 90-day
mortality was observed. Table 1 summarizes the details of
the patient characteristics and surgical procedures.
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TABLE 1 Tumor and operative characteristics of 113 patients undergoing CRS/HIPEC for PC of colorectal or appendiceal origin
Parameter Appendix tumors (n = 71, 62.8%) Colorectal carcinoma (n = 42, 37.2%) P value
Histologic type \0.001
DPAM 31 (43.7%)
PMCA 14 (19.7%)
Intestinal type AC 15 (21.1%) 37 (88.1%)
Signetring type AC 10 (14.1%) 5 (11.9%)
Adenocarcinoid 1 (1.4%)
Appearance of PC 0.015
Synchronous 47 (66.2%) 18 (42.9%)
Metachronous 24 (33.8%) 24 (57.1%)
Praeoperative Chemotherapy 17/71 (23.9%) 37/42 (88.1%) \0.001
Agents
FOLFOX/FOLFIRI only 9 17
? targeted therapy 8 20
Cycles 12 (6.5-12) 8.5 (6-12)
Postoperative Chemotherapy 24/71 (33.8%) 28/42 (66.7%) 0.001
Agents
FOLFOX/FOLFIRI only 11 7
?Targeted therapy 13 21
Cycles 12 (6–12.5) 10 (6–12)
Nodal status \0.001
pN0 20 (28.2%) 10 (23.8%)
pN1 5 (7.0%) 6 (14.3%)
pN2 7 (9.9%) 24 (57.1%)
pN3 0 1 (2.4%)
Nx 39 (54.9%) 1 (2.4%)
Grading
G1 36 (50.7%) 0 \0.001
G2 4 (5.6%) 22 (52.4%)
G3 16 (22.5%) 15 (35.7%)
Unknown 15 (21.1%) 5 (11.9%)
Surgery
Operation time (min) 580 (370–780) 504 (420–634) 0.184
Blood loss (ml) 250 (100–637.50) 200 (100–500) 0.984
Median PCI overall 15(5–27)
Median PCI subgroups 21 (8–34) 6.5 (3.75–11) \0.001
Complete CRS/HIPEC performed 47/71 (66.2%) 29/42 (69%) 0.7
PCI of completely treated patients 15 (4–25) 6 (3.5–8.5) 0.004
ICU stay (d) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.755
Hospital stay (d) 16.0 (12–24) 15.50 (12–20) 0.524
Interval data are shown as median with 1–3 interquartile range. Categorical data are shown as absolute values (n =) and percent of the respective
total patient number
Mann-Whitney U-Test was used to test for differences between groups with interval data. Comparison in categorical data was performed using
Pearson-Chi Square test
HIPEC hyperthermic intraperitoneal chemotherapy, PC peritoneal carcinomatosis, DPAM diffuse peritoneal adenomucinosis, PMCA peritoneal
mucinous carcinomatosis, AC adenocarcinoma, PCI peritoneal cancer index, ICU intensive care unit
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CSS after Complete CRS/HIPEC
After radical CRS/HIPEC, the median CSS for patients
with CRC (n = 29) was 40 months, while the median CSS
for HG appendix tumors (n = 19) has not been reached.
All patients (n = 28) with LG appendix tumors were still
alive at the time of analysis (n = 28) (Fig. 1a). Three-year
CSS rates were 74% for HG appendix tumors and 66% for
CRC. Survival of LG appendix tumors was significantly
better than for HG (p = 0.004) or CRC (p = 0.001)
patients. Remarkably, there was no difference between HG
appendix and CRC patients (p = 0.614). In contrast, sur-
vival was significantly impaired in incompletely resected
patients, with a median CSS of only 13 months for patients
with CRC (n = 13; p B 0.001) and 24 months for HG
appendix tumors (n = 21; p = 0.011). None of the three
patients with incompletely resected DPAM had died of
disease at last follow-up.
DFS after Complete CRS/HIPEC
DFS after 3 years was 26% in patients with CRC, and 38
and 96% for HG and LG appendix tumors, respectively.
Median time until recurrence of disease was 12 months for
CRC and 19 months for HG appendix neoplasms, while the
corresponding value has not been reached for LG appendix
tumors after 60 months (Fig. 1b). DFS of LG appendix
tumors was significantly better than for HG or CRC tumors
(p B 0.001 for both). In contrast, there was no difference
between HG appendix and CRC patients (p = 0.254).
Patterns of Recurrence after Complete CRS/HIPEC
A total of 34.5% of patients with PC from CRC
remained free of disease, while 65.5% developed recur-
rence during the observation period. Only 13.8% of
patients showed isolated locoregional recurrence. The
majority presented with a combination of locoregional and
distant recurrence (24.1%) or distant relapse only (27.4%).
However, recurrence included the peritoneal cavity in up to
38% of the patients, reflecting the role a local disease
control. Patients with appendix tumors showed a recur-
rence rate of 31.9%. Most recurrences were isolated in the
peritoneal cavity; only three patients developed distant
metastases. CSS was most impaired in patients with mul-
tifocal recurrence compared to patients without disease
relapse (p = 0.008), reflecting the aggressive tumor biol-
ogy in this subgroup, while patients with distant recurrence
only (p = 0.056) had a slightly better survival. An isolated
peritoneal relapse pattern was associated with the best
course of the 3 recurrence patterns (p = 0.288).
Univariate and Multivariate Analysis of Predictive
Factors
Subsequent univariate and multivariate analysis was
performed on completely resected HG tumors (n = 48; 29
CRC and 19 HG appendix tumors) only, as no patient with
DPAM died and only 3 experienced disease recurrence
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FIG. 1 CSS (a) and DFS (b) after complete CRS/HIPEC (n = 76).
a All patients with LG appendix tumors were still alive after
60 months. Median OS for HG appendix tumors has not been
reached, while it was 40 months for patients with CRC. Survival of
LG appendix tumors is significantly better than for HG (p = 0.004) or
CRC (p = 0.001) patients, respectively. In contrast, there is no
difference between HG appendix and CRC patients (p = 0.614).
b Median DFS (mDFS) was 12 months for CRC and 19 months for
HG appendix tumors. For LG appendix tumors, mDFS has not yet
been reached. DFS of LG appendix tumors is significantly better than
for HG (p B 0.001) and CRC patients (p B 0.001). In contrast, there
is no difference between HG appendix and CRC patients (p = 0.254).
Vertical bars imply censoring event. Analysis was performed via
construction of Kaplan-Meier curves. Mantel-Cox log rank test was
used to test for differences between groups
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during the observation period. A PCI of C10 and major
postoperative complications significantly influenced CSS
in univariate analysis (Table 2). The subsequently calcu-
lated multivariate model confirmed PCI of C10 and major
complications to be predictors of long-term survival and
furthermore included positive nodal status. Univariate
analysis for DFS revealed major complications and posi-
tive N stage as significant parameters. Multivariate analysis
confirmed N stage and major complications as the most
important variables and showed a trend for synchronous
appearance of PC (Table 3).
DISCUSSION
The present study observed and confirmed a survival
benefit in selected patients with PC from CRC and
appendix tumors after CRS/HIPEC. Among patients after
complete CRS/HIPEC, we identified a PCI of C10 as
negative prognostic factor for CSS, while nodal involve-
ment is a risk factor for shortened CSS and DFS. To our
surprise, major postoperative complications emerged as a
significant variable influencing both recurrence and
survival.
TABLE 2 Univariate and multivariate analysis of factors predicting cancer-specific survival in patients with high-grade tumors after complete
CRS/HIPEC (n = 48)
Variable N Median CSS (Months) Univariate analysis Multivariate analysis
p-Value Hazard ratio (95% CI) p-Value Hazard ratio (95% CI)
Age
\50 20 40 m 0.329 0.573 (0.188–1.751) – –
50 28 Not reached 0.621 –
Gender
Male 23 Not reached 0.621 0.751(0.250–2.259) – –
Female 25 Not reached –
Tumor type
HG appendix tumor 19 Not reached 0.618 – – –
CRC 29 40 m – – –
T-stage
T3 15 Not reached 0.660 – – –
T4 27 – – – –
N-stage
NO 13 48 m 0.126 – 0.015 8.336 (1.514–45.88)
N? 29 40 m – – – –
Signet-ring cell histology
No 44 Not reached 0.015 – – –
Yes 4 12 m – – – –
Temporal appearance of PC
Synchronous 22 Not reached 0.546 – – –
Metachronous 26 Not reached – – – –
Peritoneal cancer index
\10 37 Not reached 0.026 – 0.011 4.810 (1.436–16.11)
10 11 30 m – – – –
Major complication or reoperation (Clavien-Dindo-score III B)
No 44 Not reached 0.014 – 0.017 4.618 (1.317–16.20)
Yes 4 20 m – – – –
Hazard Ratios and respective p-values were calculated with cox regression analysis. To assess for bias and confounders, multivariate analysis
was performed with a backward conditional model with initial inclusion of all variables and consequent stepwise exclusion of variables until the
best model to fit the data was reached
HIPEC hyperthermic intraperitoneal chemotherapy, CRS cytoreductive surgery
Statistically significant results are bold and marked with asterisk
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Patients with PC of colorectal origin can reach a median
CSS of 40 months. Those results compare to data pub-
lished by other specialized groups reporting a median CSS
of 33 months, which is clearly superior to the median OS
of 12 months only in patients with PC treated with con-
ventional chemotherapy.2,4,14 Our survival data also
reinforce the results of the first randomized controlled trial
comparing CRS/HIPEC versus chemotherapy alone in
patients with PC from CRC, which showed a survival
benefit of a year.5,6 The median DFS of 12 months in our
patients is also comparable to reported results.2,14
The outcome for patients with HG appendix tumors is
comparable to CRC, with only 37% alive and 32% free of
disease after 5 years. These results are inferior compared to
published data, which report a 5-year OS of 59%.7 How-
ever, this cohort included PMCA only, while our analysis
incorporated patients with PMCA as well as intestinal and
signet-ring type adenocarcinomas. While no definite data
regarding the specific outcome after CRS/HIPEC of those
HG subgroups are available, it has been shown in prior
studies that outcomes for intestinal and signet-ring adeno-
carcinomas are worse than for PMCA.15–17
TABLE 3 Univariate and multivariate analysis of factors predicting disease-free survival in patients with high-grade tumors after complete
CRS/HIPEC (n = 48)
Variable N Median CSS (Months) Univariate analysis Multivariate analysis
p-Value Hazard ratio (95% CI) p-Value Hazard ratio (95% CI)
Age
\50 20 12 m 0.307 0.686 (0.333–1.413) – –
C50 28 21 m – –
Gender
Male 23 19 m 0.733 0.882 (0.430–1.810) – –
Female 25 16 m – –
Tumor type
HG appendix tumor 19 19 m 0.266 1.238 (0.850–1.804) – –
CRC 29 12 m – –
T-stage
T3 15 11 m 0.599 0.800 (0.349–1.838) – –
T4 27 21 m
N-Stage
NO 13 Not reached 0.023 4.805 (1.216–13.73) 0.016 2.804 (1.210-6.496)
N? 29 15 m
Signet-ring cell histology
No 44 19 m 0.120 2.329 (0.803–6.753) – –
Yes 4 8 m
Temporal appearance of PC
Synchronous 22 19 m 0.306 1.477 (0.700–3.116) 0.079 2.062 (0.920–4.621)
Metachronous 26 12 m
Peritoneal cancer index
\10 37 19 m 0.127 1.858 (0.839–4.117)
C10 11 16 m
Major complication or reoperation (Clavien-Dindo-score IIIB)
No 44 19 m 0.007 4.731 (1.520–14.72) 0.014 4.207 (1.333–13.27)
Yes 4 7 m
Hazard Ratios and respective p-Values were calculated with Cox Regression Analysis. To assess for bias and confounders, multivariate analysis
was performed with a backward conditional model with initial inclusion of all variables and consequent stepwise exclusion of variables until the
best model to fit the data was reached
HIPEC hyperthermic intraperitoneal chemotherapy, CRS cytoreductive surgery
Statistically significant results are bold and marked with asterisk
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In contrast, in patients with LG appendicular neoplasms,
we observed excellent long-term CSS and DFS. Although
DPAM is normally not a rapidly progressing disease,
patient morbidity still was high before the upcoming CRS/
HIPEC. Treatment consisted of repeated surgical debulk-
ing. In one of the most recent reports, median DFS after
CRS only was 24 months.18 OS within our patients with
DPAM was excellent in our analysis, as has been reported
from several other centers.7,19 Median DFS has not yet
been reached but confirms the data of other groups, which
show periods between 35 and 98 months.7,19 As a result of
the convincing data, CRS/HIPEC can today be considered
the standard of care for DPAM.
Our analyses furthermore confirmed the results of pre-
vious articles identifying positive nodal status as being an
important predictor of shortened DFS and CSS.20,21 The
observed patterns of recurrence agree with previous reports
demonstrating the worst survival for a combined recur-
rence type.22 Additionally, the amount of peritoneal
involvement significantly influences CSS. Yet this finding
is not new, and it undermines once more a key principle of
CRS: the imperative to achieve a complete resection.6 The
critical question for adequate selection remains the maxi-
mal tumor load for CRS/HIPEC. While in patients with
DPAM curative resections are possible with maximal
peritoneal dissemination, an increasing body of evidence
demonstrates a significantly decreased survival rate for
patients with CRC and a PCI of[15 or[17,
respectively.23,24
A new and substantial finding of our analysis is the
identification of major postoperative complications as a
significant risk factor influencing CSS and DFS (Fig. 2). It
is noteworthy that this impaired survival does not refer to
mortality in the postoperative course but rather to long-
term oncologic outcome. Large case series have shown that
CRS/HIPEC can be performed with acceptable morbidity
and mortality rates, which could be confirmed by analysis
of our own patient cohort.8,25 However, major complica-
tions being a risk factor for long-term survival has only
come into focus recently, with conflicting results.26 A
recent study found postoperative complications requiring
interventions to be predictive of early recurrence in CRC
patients and consequently impaired OS.27 In contrast,
another study could not find any influence of a prolonged
intensive care unit stay or readmission on long-term
survival.28
There are several possible explanations for this obser-
vation. Patients necessitating extensive resections have an
elevated risk of microscopic incomplete resections and
therefore an increased risk of early tumor recurrence.27
More extensive resections with prolonged operation time
and colonic resections also place the patient at an increased
risk for postoperative complications like fistulas or
infections.29 Infectious complications are among the most
frequent after CRS/HIPEC.25,29–31 Extensive surgical
trauma as well as sepsis lead to a phase of immunosup-
pression termed compensatory anti-inflammatory response
syndrome after an initial proinflammatory state known as
systemic inflammatory response syndrome.32,33 Occur-
rence of complications might therefore disturb the already
delicate postoperative immunological balance in these
patients, multiplying the postoperative immunosuppressive
state. It has furthermore been demonstrated that HIPEC
itself can induce immunosuppression as a result of hema-
tologic toxicity and systemic absorbance of the
chemotherapeutics used.34 Factors of HIPEC, which
influence the extent of immunosuppression, are the
chemotherapeutic agents used as well as performance of
splenectomy, which so far yields conflicting results
regarding whether it mitigates or increases hematologic
toxicity.34–36
When we consider these data together, we speculate that
the already disturbed immunological balance is further
shifted toward immunosuppression with the occurrence of
infection-entailed major complications. This might block
effective elimination of remaining systemic or peritoneal
tumor cells by cytotoxic T cells and natural killer cells.
This state of immunosuppression might also enable circu-
lating tumor cells, which can be detected in up to 50% of
patients before CRS/HIPEC, to escape elimination and
more easily seed to new, different locations.37 This would
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FIG. 2 CSS after complete CRS/HIPEC (n = 76) according to
major complications. Patients with major complications in postoper-
ative course (n = 6), defined as Clavien-Dindo IIIB or higher, had
significantly worse long-term outcome with median CSS of
34 months only compared to patients without major complications
(n = 70) (p B 0.026). Vertical bars imply censoring event. Analysis
was performed via construction of Kaplan-Meier curves. Mantel-Cox
log rank test was used to test for differences between groups
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directly affect DFS and CSS. Further research on this topic
is highly warranted.
Our study has several restrictions. It is limited by its
retrospective nature. The small sample size and low event-
to-variable ratio prevent further subgroup analysis during
Cox regression analysis and could potentially be prone to
bias. Conclusions might therefore require confirmation in
additional patient cohorts.
However, the factors identified in this study might prove
helpful in the individual preoperative assessment and
selection of patients. Major complications should be
avoided whenever possible—not only in regard to periop-
erative morbidity and mortality, but also in the interest of
the long-term oncologic outcome of patients with PC.
CONCLUSIONS
Outcomes after complete CRS/HIPEC are excellent for
LG appendix tumors. A majority of well-selected patients
with PC from CRC and HG appendix tumors will have a
survival benefit.
Extent of peritoneal tumor spread, lymph node invasion,
and major perioperative chemotherapy affect long-term
CSS after CRS/HIPEC. Adequate selection of patients and
avoidance of major complications whenever possible
therefore remains critical for CRS/HIPEC.
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